CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 250 target
Drug / intervention
Humiome ® Post LB +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06937814
NCT06937814N/ARecruitingMonitorUpdated 3mo ago · Completion was 3mo ago
Slow Enrollment
Monitor

The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers: a Double-blind, Randomized Placebo-controlled Study

dsm-firmenich Switzerland AG·interventional·Posted Apr 22, 2025·Updated Mar 9, 2026

In Brief

A clinical study evaluating Humiome ® Post LB and Placebo for GI Issues and 2 related conditions. Currently recruiting, targeting 250 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The goal of this double-blind, randomized placebo-controlled study is to evaluate the effect of an 8-week supplementation of Humiome ® Post LB (170 mg) on bowel movements in healthy adult volunteers compared to Placebo adjusted on baseline. The main question\[s\] it aims to answer \[is/are\]: Does Humiome ® Post LB improve bowel movements with self-reported GI issues? Participants will be provided Humiome ® Post LB (170 mg) for 8 weeks and asked to complete a study diary, questionnaires, and stool samples.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

N/ARecruitingOverdue
2026
First PostedApr 22, 2025
Enrollment StartJun 16, 2025
Primary CompletionApr 1, 2026
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 1.2 years ago

Interventions

Humiome ® Post LBdietary

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.

Placeboother

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.